A trial to examine the impact of natalizumab (NTZ) dose variability on serum levels and VLA-4 receptor occupancy
Latest Information Update: 10 May 2016
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics; Pharmacokinetics
Most Recent Events
- 10 May 2016 New trial record
- 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology